ATE365206T1 - Verfahren zur entwicklung von einem hiv impfstoff - Google Patents

Verfahren zur entwicklung von einem hiv impfstoff

Info

Publication number
ATE365206T1
ATE365206T1 AT99932507T AT99932507T ATE365206T1 AT E365206 T1 ATE365206 T1 AT E365206T1 AT 99932507 T AT99932507 T AT 99932507T AT 99932507 T AT99932507 T AT 99932507T AT E365206 T1 ATE365206 T1 AT E365206T1
Authority
AT
Austria
Prior art keywords
hiv
immune response
developing
hiv vaccine
inactivated
Prior art date
Application number
AT99932507T
Other languages
English (en)
Inventor
Adan Rios
Original Assignee
Adan Rios
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adan Rios filed Critical Adan Rios
Application granted granted Critical
Publication of ATE365206T1 publication Critical patent/ATE365206T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16061—Methods of inactivation or attenuation
    • C12N2740/16063—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99932507T 1998-02-13 1999-02-12 Verfahren zur entwicklung von einem hiv impfstoff ATE365206T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7464698P 1998-02-13 1998-02-13

Publications (1)

Publication Number Publication Date
ATE365206T1 true ATE365206T1 (de) 2007-07-15

Family

ID=22120781

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99932507T ATE365206T1 (de) 1998-02-13 1999-02-12 Verfahren zur entwicklung von einem hiv impfstoff

Country Status (7)

Country Link
US (2) US6383806B1 (de)
EP (1) EP1056838B1 (de)
AT (1) ATE365206T1 (de)
AU (1) AU764938B2 (de)
CA (1) CA2323011C (de)
DE (1) DE69936337T2 (de)
WO (1) WO1999041360A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6232494B1 (en) 1998-02-12 2001-05-15 Monsanto Company Process for the preparation of N-(phosphonomethyl)glycine by oxidizing N-substituted N-(phosphonomethyl)glycine
US6503753B1 (en) * 1998-02-13 2003-01-07 Adan Rios Method for the development of an HIV vaccine
US9974847B2 (en) * 2000-08-24 2018-05-22 Immunitor USA, Inc. Treatment and prevention of tuberculosis
US20030092145A1 (en) * 2000-08-24 2003-05-15 Vic Jira Viral vaccine composition, process, and methods of use
US20040236093A1 (en) * 2001-02-27 2004-11-25 Olivier Schwartz Mhc-i-restricted presentation of hiv-1 virion antigens without viral replication. application to the stimulation of ctl and vaccination in vivo; analysis of vaccinating composition in vitro
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
EP1727894A1 (de) 2004-03-22 2006-12-06 Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Zell und virale inaktivierung
US8613934B2 (en) 2004-03-22 2013-12-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cellular and viral inactivation
US8278083B2 (en) 2004-03-22 2012-10-02 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Inactivated influenza virus compositions
KR100568542B1 (ko) * 2004-08-19 2006-04-07 삼성전자주식회사 자기 램 소자의 기록방법
CN101056977B (zh) * 2004-10-04 2013-01-30 拜欧瓦克西姆有限公司 用于治疗hiv感染患者的亚型匹配的灭活全病毒疫苗
CA2735724C (en) 2008-06-19 2018-07-24 Variation Biotechnologies Inc. Compositions and methods for treating influenza
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
JP5854559B2 (ja) 2009-07-06 2016-02-09 ヴァリエーション バイオテクノロジーズ インコーポレイテッド 小胞を調製する方法及びこれから製造される製剤
US8367315B2 (en) * 2010-03-05 2013-02-05 Adan Rios Inactivation of reverse transcriptases by azido-diarylpyrimidines
WO2012006367A2 (en) 2010-07-06 2012-01-12 Variation Biotechnologies, Inc. Compositions and methods for treating influenza
US10736844B2 (en) 2011-01-13 2020-08-11 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
AU2013208693B2 (en) 2012-01-12 2017-12-07 Variation Biotechnologies Inc. Compositions and methods for treating viral infections
EP2806894A4 (de) 2012-01-27 2015-11-04 Variation Biotechnologies Inc Verfahren und zusammensetzungen für therapeutika

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256767A (en) 1987-06-10 1993-10-26 The Immune Response Corporation Retroviral antigens
US5861282A (en) 1989-10-16 1999-01-19 Whitehead Institute For Biomedical Research Non-infectious HIV particles and uses therefor
US5849475A (en) 1990-10-12 1998-12-15 Benjamin Rovinski et al Immunoassay diagnostic kit containing antigens derived from self-assembled, non-infectious, non-replicating, immunogenic retrovirus-like particles comprising modified HIV genomes and chimeric envelope glycoproteins
US6080408A (en) 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles

Also Published As

Publication number Publication date
EP1056838B1 (de) 2007-06-20
US6653130B2 (en) 2003-11-25
EP1056838A1 (de) 2000-12-06
CA2323011A1 (en) 1999-08-19
AU764938B2 (en) 2003-09-04
DE69936337T2 (de) 2008-02-21
DE69936337D1 (de) 2007-08-02
AU3293799A (en) 1999-08-30
WO1999041360A1 (en) 1999-08-19
CA2323011C (en) 2013-01-15
US20030129200A1 (en) 2003-07-10
US6383806B1 (en) 2002-05-07

Similar Documents

Publication Publication Date Title
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
ATE396739T1 (de) Entwicklung einer vakzine zur prävention von infektionen mit filovirus bei primaten
DK0584348T3 (da) Genetisk vaccine mod immundefektvirusser
DE69632235D1 (de) Newcastle-Krankheitsvirus-Kombinationsimpfstoff
ES2187530T3 (es) Peptidos para reducir respuestas de linfocito t ctitotoxicos al virus de la hepatitis b.
CY1106785T1 (el) Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
DE60144240D1 (de) Zusammensetzung mit immunogenen mikroteilchen
DE69933433D1 (de) Virus enthaltende zusammensetzungen und methoden zur konzentration von viruspräparaten
MXPA02007478A (es) Vacuna contra el virus de inmunodeficiencia humana.
ATE426412T1 (de) Adjuvante influenza-vakzine
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
DK1542732T3 (da) Fusionsproteiner af Mycobacterium tuberculosis
DK0534618T3 (da) Peptider til fremkaldelse af cytotoksiske T-lymfocytreaktioner mod hepatitis B-virus
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
DE69533067D1 (de) Hepatis e-virus antigene und dessen verwendungen
CO5280138A1 (es) Virus atenuados e inocuos de la diarrea virica bovina para en vacas gestantes
EA200301151A1 (ru) Вакцина против натуральной оспы
ATE278795T1 (de) Herpesviren für die modulation einer immunantwort
DE60231821D1 (de) Rekombinante tollwut-vakzine und verfahren zu ihrer herstellung und verwendung
ATE505482T1 (de) Impfstoff gegen infektiöses lachsanämievirus
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
DE68920345D1 (de) Lebendes Kombinationsvakzin.
SE8700466D0 (sv) Vaccines against melanoma
ES2055610T3 (es) Vacuna contra hrsv.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties